comparemela.com
9
10
11
12
13
14
15
Latest Breaking News On - Herriot tabuteau - Page 8 : comparemela.com
Mizuho Securities Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price .
New-york
United-states
Graig-suvannavejh
Axsome-therapeutics-inc
Mizuho-securities
Axsome-therapeutics
Research-report
Bioxcel-therapeutics
Moderate-buy
Herriot-tabuteau
Morgan Stanley Reaffirms Their Hold Rating on Axsome Therapeutics (AXSM)
In a report released on March 24, Vikram Purohit from Morgan Stanley maintained a Hold rating on Axsome Therapeutics (AXSM – Research Repo.
New-york
United-states
Ascendis-pharma
Vikram-purohit
Morgan-stanley
Axsome-therapeutics-inc
Axsome-therapeutics
Research-report
Moderate-buy
Herriot-tabuteau
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to the Axsome Therapeutics Conference Call. Currently, all participants are in listen-only mode.
Herriot-tabuteau
Marc-goodman
Lori-englebert
Mark-jacobson
Charles-duncan
Nick-pizzie
Exchange-commission
Cantor-fitzgerald
Axsome-therapeutics-inc
Health-photo
Nasdaq
Form 8-K Axsome Therapeutics, For: Feb 27
Form 8-K Axsome Therapeutics, For: Feb 27
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New-york
United-states
Delaware
Washington
Herriot-tabuteau
Exchange-act-or-securities
Axsome-therapeutics-inc
Securities-exchange
Commission-file-number
Securities-exchange-act
Its-charter
Principal-executive-offices
Axsome Therapeutics (AXSM) Q4 2022 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2022.
Hunter-murdock
Herriot-tabuteau
Matt-kaplan
Joe-thome-cowen
Charles-duncan
Nick-pizzie
Jason-gerberry
Graig-suvannavejh
Charles-duncan-cantor-fitzgerald
Joon-lee-truist
Robert-hazlett
vimarsana © 2020. All Rights Reserved.